9-Week Cancer Treatment Keeps 32 Patients Cancer-Free 3 Years

Thirty-two colorectal cancer patients walked into a UK trial expecting months of grueling chemotherapy after surgery. Instead, they got nine weeks of immunotherapy before surgery, and three years later, not one has seen their cancer return.

The NEOPRISM-CRC study, led by researchers at University College London and University College London Hospitals, flipped the traditional treatment approach on its head. Patients with stage two or three colorectal cancer received pembrolizumab for just nine weeks before undergoing surgery, skipping the usual six months of post-surgery chemotherapy entirely.

The results speak for themselves. After 33 months of follow-up, zero patients have experienced a relapse. That includes both patients whose tumors completely disappeared and those who still had traces of cancer after treatment.

Under standard care, about one in four patients see their cancer return within three years. This new approach appears to offer something far more powerful: lasting protection that strengthens over time rather than fading.

Dr. Kai-Keen Shiu, the trial's chief investigator, calls the zero recurrence rate "extremely encouraging." But the team didn't stop at proving the treatment works. They developed personalized blood tests that detect cancer DNA in the bloodstream, allowing doctors to predict early whether the treatment is succeeding.

The trial focused on a specific genetic subtype of colorectal cancer that affects about 2,000 to 3,000 UK patients each year. These tumors typically respond poorly to chemotherapy but appear highly vulnerable to immunotherapy.

Christopher Burston, a 73-year-old patient from Dorset, joined the trial after routine screening detected his cancer in February 2023. He represents one of 32 lives transformed by rethinking when and how to fight cancer.

Why This Inspires

This breakthrough shows that sometimes doing less at the right time beats doing more at the wrong time. Nine weeks of targeted treatment before surgery proved more effective than months of chemotherapy afterward.

The personalized blood tests mean patients might soon know within weeks whether their treatment is working, sparing them unnecessary procedures and offering peace of mind far earlier. Researchers can now identify which patients need more aggressive treatment and which can safely skip additional therapy.

Bowel cancer remains the fourth most common cancer in the UK, with 44,000 new cases yearly. While survival rates reach 90% when caught at stage one, they plummet to just 10% at stage four. Innovations like this could shift thousands of patients from the worried majority to the cancer-free minority.

The findings were presented at the American Association for Cancer Research Annual Meeting 2026 in San Diego, giving the global oncology community a new template for tackling one of medicine's toughest challenges.

Thirty-two patients took a chance on a different path, and three years later, they're all still walking it cancer-free.